Gilead Moves To Block Harvoni Infringer In India
This article was originally published in Scrip
Executive Summary
Gilead Sciences has moved court to block an alleged copy of its blockbuster hepatitis C treatment, Harvoni (sofosbuvir/ledipasvir), in India which it believes not only wrongly rides on the brand name but may also not have the requisite regulatory approvals.
You may also be interested in...
Cadila-Hetero Slugfest Over The 'Hep' Tag
Trademark disputes continue unabated in Indian courts, this time involving generic versions of Bristol-Myers Squibb's hepatitis C therapy, Daklinza (daclatasvir) marketed by the local firms Cadila Healthcare and Hetero.
India IPR Realities: Pharma, Legal Heads Discuss Winds Of Change, ‘Damocles Sword’
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.
India IPR Wheels Are Turning: Novartis, Bayer, Sun, Legal Heads Discuss Realities
Leaders from Novartis, Bayer, Sun Pharma, the Indian Pharmaceutical Alliance, Médecins Sans Frontières and Anand and Anand discuss India’s evolving intellectual property rights landscape, including pre-grant oppositions, enforcement action and other realities. Concerns around evergreening, restrictions on patent-eligible subject matter and compulsory licensing were also key talking points at a recent conference in Hyderabad.